Literature DB >> 1820335

The first clinical description of Balkan endemic nephropathy (1956) and its validity 35 years later.

Y Tanchev1, D Dorossiev.   

Abstract

A high prevalence of renal disease in Vratza, a district in north-west Bulgaria, was studied in 1950-54 by Tanchev at the district hospital. A particular unknown renal condition was described at local meetings in 1953 and was referred to as 'endemic Vratza nephritis' in 1955. The first clinical description of this new nosological entity, published by Tanchev and colleagues in 1956, was based on 664 patients hospitalized for renal disease. Of 296 with chronic nephritis, 17 died in hospital and 103 died a few days later at home, all with uraemia, to give a total of 40.5%. Peasants formed the majority of the patients (85.7%), and 4-43 came from only 16 villages and 1-3 from 36 villages; none came from the remaining 21 villages in the district. Clusters of patients were thus noted in villages, families and even houses. The patients had the following common characteristics: from endemic areas; other renal ailments in the family; copper-yellow skin and orange palms and soles; normochromic anaemia; absence of acute onset, considerable albuminuria, hypertension and oedema; no compensatory polyuria; azotaemia progressing insidiously to fatal uraemia; 83.5% died within one year of the appearance of symptoms. After similar ailments were described in Yugoslavia in 1957 and Romania in 1961, the condition became known as Balkan endemic nephropathy. The etiology of this disease remains unknown, and no treatment is available, although haemodialysis and kidney transplants have prolonged patients' survival.

Entities:  

Mesh:

Year:  1991        PMID: 1820335

Source DB:  PubMed          Journal:  IARC Sci Publ        ISSN: 0300-5038


  8 in total

Review 1.  Balkan endemic nephropathy: still a mysterious disease.

Authors:  Z Bozić; V Duancić; M Belicza; O Kraus; I Skljarov
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

2.  Chronic kidney disease of unknown aetiology and ground-water ionicity: study based on Sri Lanka.

Authors:  M W C Dharma-Wardana; Sarath L Amarasiri; Nande Dharmawardene; C R Panabokke
Journal:  Environ Geochem Health       Date:  2014-08-14       Impact factor: 4.609

3.  Limitations and plausibility of the Pliocene lignite hypothesis in explaining the etiology of Balkan endemic nephropathy.

Authors:  S V M Maharaj
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

4.  The role of a parental history of Balkan endemic nephropathy in the occurrence of BEN: a prospective study.

Authors:  Kesinee Hanjangsit; Wilfried Karmaus; Plamen Dimitrov; Hongmei Zhang; Jim Burch; Svetla Tzolova; Vecihi Batuman
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-04-04

5.  A pilot study of nuclear instability in archived renal and upper urinary tract tumours with putative ochratoxin aetiology.

Authors:  Peter G Mantle; Cyrille Amerasinghe; Amy L Brown; Diana Herman; Thomas Horn; Thoger Krogh; Edward W Odell; Tomas Rosenbaum; Calin A Tatu
Journal:  Toxins (Basel)       Date:  2010-03-09       Impact factor: 4.546

6.  Comparative (1)H NMR metabolomic urinalysis of people diagnosed with Balkan endemic nephropathy, and healthy subjects, in Romania and Bulgaria: a pilot study.

Authors:  Peter Mantle; Mirela Modalca; Andrew Nicholls; Calin Tatu; Diana Tatu; Draga Toncheva
Journal:  Toxins (Basel)       Date:  2011-07-04       Impact factor: 4.546

7.  Increased blood pressure in adult offspring of families with Balkan endemic nephropathy: a prospective study.

Authors:  Plamen S Dimitrov; Valeri A Simeonov; Svetlana D Tsolova; Angel G Bonev; Rossitza B Georgieva; Wilfried J Karmaus
Journal:  BMC Nephrol       Date:  2006-08-23       Impact factor: 2.388

8.  Metals and kidney markers in adult offspring of endemic nephropathy patients and controls: a two-year follow-up study.

Authors:  Wilfried Karmaus; Plamen Dimitrov; Valeri Simeonov; Svetla Tsolova; Angel Bonev; Rossitza Georgieva
Journal:  Environ Health       Date:  2008-04-03       Impact factor: 5.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.